PATENTING REJECTION OVER A PENDING SECONDAR LICATION

Docket No. 18810-80090

ln re Ap	plication of:	Heaney et al.	7	APD	2 R	2063 🖏	
Applicat	Application No. 09/730,469			~ MIN	7 0		4
Filed:		December 4, 2000	'	TE.			à
For: Methods Of Using Pituitary Tumor Transforming Gene (FLPG) Carboxy-Terminal Peptides To Inhibit Neoplastic Cellular Proliferation And/Or Transformation Of Breast And Ovarian Cells							
The owner, CEDARS-SINAI MEDICAL CENTER of 100. percent interest in the instant application hereby disclaims, except as provided below, the terminal part of the statutory term of any patent granted on the instant application, which would extend beyond the expiration date of the full statutory term defined in 35 U.S.C. 154 to 156 and 173 as shortened by any terminal disclaimer filed prior to the grant of any patent granted on pending second Application Number 09/569,956 , filed on May 12, 2000 The owner hereby agrees that any patent so granted on the instant application shall be enforceable only for and during such period that it and any patent granted on the second application are commonly owned. This agreement runs with any patent granted on the instant application and is binding upon grantee, its successors or assigns.							
In making the above disclaimer, the owner does not disclaim the terminal part of any patent granted on the instant application that would extend to the expiration date of the full statutory term as defined in 35 U.S.C. 154 to 156 and 173 of any patent granted on the second application, as shortened by any terminal disclaimer filed prior to the patent grant, in the event that any such granted patent: expires for failure to pay a maintenance fee, is held unenforceable, is found invalid by a court of competent jurisdiction, is statutorily disclaimed in whole or terminally disclaimed under 37 CFR 1.321, has all claims cancelled by a reexamination certificate, is reissued, or in any manner terminated prior to the expiration of its full statutory term as shortened by any terminal disclaimer filed prior to its grant.							
Check either box 1 or 2, if appropriate.							
1.	1. ☐ For submissions on behalf of an organization (e.g., corporation, partnership, university, government agency, etc.), the undersigned is empowered to act on behalf of the organization.						
I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful statements may jeopardize the validity of the application or any patent issued thereon.							
2.	2. 🔼 The undersigned is an attorney of record.						
3. Owner/applicant is ⊠ Small entity ☐ Large entity							
The terminal disclaimer fee under 37 CFR 1.20(d) is and is to be paid as follows:							
☐ A check in the amount of the fee is enclosed.							
The Commissioner is hereby authorized to charge any fees which may be required, or credit any overpayment, to Deposit Account Number 50-1597 A duplicate copy of this sheet is enclosed.							
PTO suggested wording for terminal disclaimer was							
unchanged. changed (if changed, an explanation should be supplied.) APR 3 0 2003							
Man Signature Dated: April 21, 2003 TECH CENTER 160 1/29							ممه
							300
Name and Address of Person Signing April 21, 2003 with the U.S. Postal Service as fi class mail under 37 C.F.R. 1.8 and is addressed to the class mail under 37 C.F.R. 1.8 and is addressed to the class mail under 37 C.F.R. 1.8 and is addressed to the class mail under 37 C.F.R. 1.8 and is addressed to the class mail under 37 C.F.R. 1.8 and is addressed to the class mail under 37 C.F.R. 1.8 and is addressed to the class mail under 37 C.F.R. 1.8 and is addressed to the class mail under 37 C.F.R. 1.8 and is addressed to the class mail under 37 C.F.R. 1.8 and is addressed to the class mail under 37 C.F.R. 1.8 and is addressed to the class mail under 37 C.F.R. 1.8 and is addressed to the class mail under 37 C.F.R. 1.8 and is addressed to the class mail under 37 C.F.R. 1.8 and is addressed to the class mail under 37 C.F.R. 1.8 and is addressed to the class mail under 37 C.F.R. 1.8 and is addressed to the class mail under 37 C.F.R. 1.8 and is addressed to the class mail under 37 C.F.R. 1.8 and is addressed to the class mail under 37 C.F.R. 1.8 and is addressed to the class mail under 38 C.F.R. 1.8 and is addressed to the class mail under 38 C.F.R. 1.8 and is addressed to the class mail under 38 C.F.R. 1.8 and is addressed to the class mail under 38 C.F.R. 1.8 and is addressed to the class mail under 38 C.F.R. 1.8 and is addressed to the class mail under 38 C.F.R. 1.8 and is addressed to the class mail under 38 C.F.R. 1.8 and is addressed to the class mail under 38 C.F.R. 1.8 and is addressed to the class mail under 38 C.F.R. 1.8 and is addressed to the class mail under 38 C.F.R. 1.8 and is addressed to the class mail under 38 C.F.R. 1.8 and is addressed to the class mail under 38 C.F.R. 1.8 and is addressed to the class mail under 38 C.F.R. 1.8 and is addressed to the class mail under 38 C.F.R. 1.8 and is addressed to the class mail under 38 C.F.R. 1.8 and is addressed to the class mail under 38 C.F.R. 1.8 and is addressed to the class mail under 38 C.F.R. 1.8 and is addressed to the class mail under 38 C.F.R. 1.8 and						class mail under 37 C.F.R. 1.8 and is addressed to the	
	Registration No. 40,345 Assistant Commissioner for Patents, Washington, D.C.						
SIDLEY AUSTIN BROWN & WOOD LLP							
555 West Fifth Street Signature of Rerson Mailing Correspon						Signature of Rerson Mailing Correspondence	
Los Angeles, CA 90013-1010 Ofc: 213/896-6665							
Fax: 213/896-6600 Ann Weiss							
- ua. #it	-,070-0000		8	914		Typed or Printed Name of Person Mailing Correspondence	